Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

A booming gray market is turning kitchens into makeshift pharmacies as Americans chase cheaper alternatives to high-priced ...

SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself with weight-loss drugs, two of ...

April Wilkerson builds a DIY pot and pan pullout to improve cabinet access and organization.

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.